

Expression of inflammation-mediated cluster of genes as a new marker of canine mammary malignancy

K. M. Pawłowski · A. Homa · M. Bulkowska ·
K. Majchrzak · T. Motyl · M. Król

Accepted: 13 February 2013 / Published online: 24 February 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Because canine mammary tumours constitute a serious clinical problem and there are no good prognostic markers (only histopathological variables are used), the aim of the presented study was to find new malignancy markers as well as to identify intracellular pathways and biological processes characteristic for canine mammary malignancy. We compared gene expression of the most malignant mammary tumours (poorly differentiated cancers of the 3rd grade of malignancy) with less malignant tumours (well differentiated cancers of the 1st grade of malignancy). The results of our study indicated that in dogs the number of tumour-infiltrating myeloid cells or expression of myeloid-specific antigens by cancer cells is related to the cancer progression and may constitute a new marker of malignancy, however further studies in this field are required.

Keywords Canine mammary cancer · Malignancy markers · Microarrays · Real-time qPCR · Myeloid cells infiltration

K. M. Pawłowski · A. Homa · M. Bulkowska · T. Motyl ·
M. Król (✉)
Department of Physiological Sciences,
Faculty of Veterinary Medicine, Warsaw University
of Life Sciences—WULS, Nowoursynowska 159,
02-776 Warsaw, Poland
e-mail: magdalena_krol@sggw.pl

K. M. Pawłowski
Department of Large Animal Diseases with Clinic,
Faculty of Veterinary Medicine, Warsaw University
of Life Sciences—WULS, Nowoursynowska 100,
02-797 Warsaw, Poland

K. Majchrzak
Department of Animal Environment Biology,
Faculty of Animal Sciences, Warsaw University
of Life Sciences—WULS, Ciszewskiego 8,
02-786 Warsaw, Poland

Introduction

Spontaneous mammary tumours are the most prevalent type of malignant neoplasm in the bitch and woman with the three times over incidence in dog (MacEwen 1990). About 50 % of all the mammary tumours are malignant (Misdorp 2002). The aetiology of mammary cancer is very complex and not clearly understood. The known mediators of tumorigenesis in both species are: genetic, hormonal, dietary, environmental and carcinogenic factors (Russo and Russo 1998). Moreover, both species live in the same conditions, thus the dog is a good model for breast cancer studies.

The role of oestrogens, progestins and growth hormone in canine mammary cancer development has been documented (Pawłowski et al. 2012). That is why mainly affected are not spayed female dogs in the middle age. The early ovariectomy reduces risk of mammary cancer development (Misdorp 1991). However, the high morbidity and mortality rate, which is caused by poor diagnostics and ineffective treatment strategies makes this problem still actual in both humans and dogs. The conventional approach to cancer therapy provide treatment according to the organ in which the cancer originates. However, different intracellular signalling pathways are perturbed in the various cancers even if they represent the same type. Thus, the patients with the same type of cancer often have dissimilar genetic defects in their tumours and respond in a heterogeneous manner to anticancer agents (Veer van't and Bernards 2008). Moreover, the diagnostic methodologies available in veterinary oncology may still be considered to be in progress. So far, only histopathological variables (tumour size, lymph node status, vascular invasion and tumour grade of differentiation) are used as prognostic parameters (Manuali et al. 2012).

Thus, the aim of the presented study was to find intracellular pathways and biological processes characteristic for canine mammary malignancy. We compared gene expression of the most malignant mammary tumours (poorly differentiated

Table 2 The list of up-regulated genes (↑) in canine mammary cancers of the 3rd grade of malignancy compared with the canine mammary cancers of the 1st grade of malignancy. Data was analyzed using Gene Spring software (Agilent, USA), $p < 0.005$, Fold change > 3

	Fold Change	Gene symbol	Description
1	↑5.0125217	IL8	Canis lupus familiaris interleukin 8 (IL8), mRNA [NM_001003200]
2	↑4.714284	FABP1	Fatty acid binding protein Fragment [Source:UniProtKB/TrEMBL;Acc:Q95KW5] [ENSCRAFT00000011880]
3	↑4.2913084	MMP1	Matrix metalloproteinase 1
4	↑4.2044907	EXTL3	Exostosin-like 3;EXTL3;ortholog
5	↑3.957821	CNGA1	Canis lupus familiaris cyclic nucleotide gated channel alpha 1 (CNGA1), mRNA [NM_001003222]
6	↑3.925793	NELL2	PREDICTED: Canis familiaris similar to Protein kinase C-binding protein NELL2 precursor (NEL-like protein 2) (Nel-related protein 2), transcript variant 2 (LOC477636), mRNA [XM_846523]
7	↑3.9208682	CNGA1	Canis lupus familiaris cyclic nucleotide gated channel alpha 1 (CNGA1), mRNA [NM_001003222]
8	↑3.416843	MMP3	Canis lupus familiaris matrix metalloproteinase 3 (stromelysin 1, progelatinase) (MMP3), mRNA [NM_001002967]
9	↑3.2882302	NELL2	NEL-like 2 (chicken) [Source:HGNC Symbol;Acc:7751] [ENSCRAFT00000015264]
10	↑3.0424755	MTMR10	PREDICTED: Canis familiaris similar to phosphatidylinositol-3-phosphatase associated protein, transcript variant 4 (LOC479016), mRNA [XM_851476]
11	↑2.972987	ADCY8	adenylate cyclase 8 (brain) [Source:HGNC Symbol;Acc:239] [ENSCRAFT00000001672]
12	↑2.596691	MARCO	macrophage receptor with collagenous structure [Source:HGNC Symbol;Acc:6895] [ENSCRAFT00000007902]
13	↑2.486832	EMR3	Canis lupus familiaris egf-like module containing, mucin-like, hormone receptor-like 3 (EMR3), mRNA [NM_001038666]
14	↑2.31884	IL6	Canis lupus familiaris interleukin 6 (interferon, beta 2) (IL6), mRNA [NM_001003301]
15	↑2.2737932	SRGN	PREDICTED: Canis familiaris similar to Secretory granule proteoglycan core protein precursor (Platelet proteoglycan core protein) (P.PG) (Hematopoietic proteoglycan core protein) (Serglycin) (LOC609421), mRNA [XM_846674]
16	↑2.1735125	ELSPBP1	Epididymal sperm-binding protein 1;ELSPBP1;ortholog
17	↑2.1602907	LEF1	PREDICTED: Canis familiaris similar to lymphoid enhancer binding factor-1, transcript variant 7 (LOC478507), mRNA [XM_858241]
18	↑2.1465235	GAD1	Canis lupus familiaris glutamate decarboxylase 1 (brain, 67 kDa) (GAD1), mRNA [NM_001097543]
19	↑2.0999904	CTRB1	PREDICTED: Canis familiaris similar to chymotrypsinogen B1, transcript variant 1 (LOC479650), mRNA [XM_536782]
20	↑2.0861115	IL15	Interleukin-15;IL15;ortholog
21	↑2.001695	DDIT3	DNA-damage-inducible transcript 3 [Source:HGNC Symbol;Acc:2726] [ENSCRAFT00000000367]
22	↑1.975823	PCSK2	proprotein convertase subtilisin/kexin type 2 [Source:HGNC Symbol;Acc:8744] [ENSCRAFT000000008876]
23	↑1.9757178	GPM6A	PREDICTED: Canis familiaris similar to glycoprotein M6A isoform 1, transcript variant 6 (LOC475641)
24	↑1.9687057	HLA-DQB1	Canis lupus familiaris major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1), mRNA [NM_001014381]
25	↑1.9438797	SLC30A8	solute carrier family 30 (zinc transporter), member 8 [Source:HGNC Symbol;Acc:20303] [ENSCRAFT00000001287]
26	↑1.9432139	LYZL6	Q6UW30_HUMAN (Q6UW30) TKAL754, partial (63 %) [TC51642]
27	↑1.8990102	CDA	cytidine deaminase [Source:HGNC Symbol;Acc:1712] [ENSCRAFT000000023893]
28	↑1.8836564	NELL1	PREDICTED: Canis familiaris similar to nel-like 1 precursor (LOC476888), mRNA [XM_534090]
29	↑1.8206882	CELA1	Canis lupus familiaris chymotrypsin-like elastase family, member 1 (CELA1), mRNA [NM_001003007]
30	↑1.8029478	CAMP	Canis lupus familiaris cathelicidin antimicrobial peptide (CAMP), mRNA [NM_001003359]
31	↑1.7610306	ERGIC2	Endoplasmic reticulum-Golgi intermediate compartment protein 2;ERGIC2;ortholog
32	↑1.7566903	PRKCQ	protein kinase C, theta [Source:HGNC Symbol;Acc:9410] [ENSCRAFT000000008336]

Table 2 (continued)

	Fold Change	Gene symbol	Description
33	↑1.7566395	TFPI2	tissue factor pathway inhibitor 2 [Source:HGNC Symbol;Acc:11761] [ENSCAFT00000023103]
34	↑1.7506666	LAMP3	lysosomal-associated membrane protein 3 [Source:HGNC Symbol;Acc:14582] [ENSCAFT00000018703]
35	↑1.725342	S100P	S100 calcium binding protein P [Source:HGNC Symbol;Acc:10504] [ENSCAFT00000022770]
36	↑1.7065927	TREM1	triggering receptor expressed on myeloid cells 1 [Source:HGNC Symbol;Acc:17760] [ENSCAFT00000002493]
37	↑1.6830823	BCL2A1	BCL2-related protein A1 [Source:HGNC Symbol;Acc:991] [ENSCAFT00000022179]
38	↑1.6449332	IL33	Canis lupus familiaris interleukin 33 (IL33), mRNA [NM_001003180]
39	↑1.597691	AREGB	amphiregulin B

protein expression was performed (data not shown). The tumour types of specimens were classified based on the World Health Organization (WHO) Histological Classification and Mammary Tumours of the Dog and Cat classification (Misdorp et al. 1999). Histological tumour grading was conducted on HE-stained sections using a Misdorp classification (2002). The mammary carcinoma grading was assessed in respect to tubule formation, degree of differentiation and mitotic index as. All the tumours examined were classified as the 1st grade of malignancy or the 3rd grade of malignancy (6 tumours in each group). Unfortunately survival data of these dogs is unavailable.

Microarray analyses

The total RNA from the samples was isolated using a Total RNA kit (A&A Biotechnology, Poland) according to the manufacturer's protocol. Isolated RNA samples were dissolved in RNase-free water. The quantity of RNA was measured using NanoDrop (NanoDrop Technologies USA). The samples with adequate amounts of RNA were treated with DNaseI to eliminate a possibility of DNA contamination. The samples were subsequently purified using RNeasy MiniElute Cleanup Kit (Qiagen, Germany). Finally RNA samples were analyzed using BioAnalyzer (Agilent, USA) to measure the final RNA quality and integrity.

The Quick Amp Labeling Kit (Agilent, USA) was used to amplify and label target RNA to generate complementary RNA (cRNA) for oligo microarrays used in gene expression profiling and other downstream analyses. The gene expression of the poorly differentiated, most malignant tumours was compared against the gene expression of the well differentiated tumours (the 1st grade of malignancy). Samples were examined in four repetitions (two dye-swaps to eliminate the effect of label factor). Thus, each biological condition was labelled once by Cy3 and once by Cy5. Taking the

average of all labelled arrays, the dye effect on any particular gene was cancelled. The hybridization was performed with canine-specific AMADID Release GE 4x44K microarrays (Agilent, USA) using Gene Expression Hybridization Kit (Agilent, USA) according to the manufacturer's protocol.

Signal detection, quantification and analysis

Acquisition and analysis of hybridization intensities were performed using DNA microarray scanner (Agilent, USA). Then, the results were extracted using Agilent's Feature Extraction Software with normalization and robust statistical analyses. Results were analyzed for statistical purposes using Future Extraction and Gene Spring software (Agilent, USA). The unpaired t-test with Benjamin-Hochberg FDR < 5 % (false discovery rate) correction was applied (with *p* value cut-off < 0.01). For further analysis we chose only these genes with values within upper and lower cut-off (100.00 and 20.00, respectively) in each of the slide, whose expression changed at least 1.5-fold in each of examined slide. The area of the analyses covered in this publication has been deposited in NCBI's Gene Expression Omnibus and is accessible via GEO Series accession number GSE 44033.

Gene function was identified using the PANTHER pathway analysis software (Mi et al. 2005) and Pathway Studio software (Agilent, USA). PANTHER online platform allowed for wide analysis of the *Canis familiaris* regulated genes and also for statistical analysis of number of regulated genes involved in specific pathways or biological functions compared to the normal healthy cell of this specie.


Real-time qPCR

The mRNA sequences of the key genes were obtained from NCBI database. Primers were designed using PRIMER3 software (free on-line access) and checked using Oligo

Table 3 The list of down-regulated genes (↓) in canine mammary cancers of the 3rd grade of malignancy compared with the canine mammary cancers of the 1st grade of malignancy. Data was analyzed using Gene Spring software (Agilent, USA), $p < 0.005$, Fold change > 1.5

	Fold Change	Gene Symbol	Description
1	↓1.5897567	SMOC1	SPARC related modular calcium binding 1 [Source:HGNC Symbol;Acc:20318] [ENSCAFT00000026288]
2	↓1.6253631	SERPINE1	Canis lupus familiaris serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 (SERPINE1), mRNA [NM_001197095]
3	↓1.6317778	GDPD2	glycerophosphodiester phosphodiesterase domain containing 2 [Source:HGNC Symbol;Acc:25974] [ENSCAFT00000026677]
4	↓1.6928551	TTC17	tetratricopeptide repeat domain 17 [Source:HGNC Symbol;Acc:25596] [ENSCAFT00000010834]
5	↓1.7700043	PIP	prolactin-induced protein [Source:HGNC Symbol;Acc:8993] [ENSCAFT00000005869]
6	↓1.9344714	PPP2R2B	PREDICTED: Canis familiaris similar to protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform isoform 1, transcript variant 1 (LOC478053), mRNA [XM_535231]
7	↓1.9801016	ACAN	Canis lupus familiaris aggrecan (ACAN), mRNA [NM_001113455]
8	↓2.0213842	BMP7	Bone morphogenetic protein 7 Fragment (BMP-7)(Osteogenic protein 1)(OP-1) [Source:UniProtKB/Swiss-Prot;Acc:P34819] [ENSCAFT00000019076]
9	↓2.0953069	PPP6R3	PREDICTED: Canis familiaris similar to sporulation-induced transcript 4-associated protein, transcript variant 7 (LOC483688), mRNA [XM_858601]
10	↓2.2811608	NOTUM	notum pectinacylesterase homolog (Drosophila) [Source:HGNC Symbol;Acc:27106] [ENSCAFT00000009543]
11	↓2.3086379	PRSS16	protease, serine, 16 (thymus) [Source:HGNC Symbol;Acc:9480] [ENSCAFT00000017667]
12	↓2.3557005	LRP2	low density lipoprotein receptor-related protein 2 [Source:HGNC Symbol;Acc:6694] [ENSCAFT00000019396]
13	↓2.3743253	FMOD	fibromodulin [Source:HGNC Symbol;Acc:3774] [ENSCAFT00000015038]
14	↓2.3969395	FABP3	fatty acid binding protein 3, muscle and heart (mammary-derived growth inhibitor) [Source:HGNC Symbol;Acc:3557] [ENSCAFT00000017685]
15	↓2.5347118	LALBA	Canis lupus familiaris lactalbumin, alpha- (LALBA), mRNA [NM_001003129]
16	↓2.630961	MYOC	Canis lupus familiaris myocilin, trabecular meshwork inducible glucocorticoid response (MYOC), mRNA [NM_001048030]
17	↓2.7111955	LOX	lysyl oxidase [Source:HGNC Symbol;Acc:6664] [ENSCAFT00000000805]
18	↓2.7223504	SLC22A10	solute carrier family 22, member 10 [Source:HGNC Symbol;Acc:18057] [ENSCAFT00000024230]
19	↓2.7353601	COL2A1	Canis lupus familiaris collagen, type II, alpha 1 (COL2A1), mRNA [NM_001006951]
20	↓2.74712	ACSM4	acyl-CoA synthetase medium-chain family member 4 [Source:HGNC Symbol;Acc:32016] [ENSCAFT00000028528]
21	↓2.8774078	PAQR8	progesterin and adipoQ receptor family member VIII [Source:HGNC Symbol;Acc:15708] [ENSCAFT00000003464]
22	↓3.2135046	MGAT4C	mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme C (putative) [Source:HGNC Symbol;Acc:30871] [ENSCAFT00000009653]
23	↓3.331683	EPYC	epiphycan [Source:HGNC Symbol;Acc:3053] [ENSCAFT00000009916]
24	↓3.341357	SERPINA9	serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 9 [Source:HGNC Symbol;Acc:15995] [ENSCAFT00000028000]
25	↓3.625558	FXYD2	FXYD domain containing ion transport regulator 2 [Source:HGNC Symbol;Acc:4026] [ENSCAFT00000020395]
26	↓4.1011486	SCG2	PREDICTED: Canis familiaris similar to Secretogranin-2 precursor (Secretogranin II) (SgII) (Chromogranin C), transcript variant 1 (LOC488550), mRNA [XM_545669]
27	↓4.2103615	RIPPLY1	PREDICTED: Canis familiaris similar to Down syndrome critical region homolog 6 (LOC610288), mRNA [XM_847751]
28	↓4.6913886	TAF7L	TAF7-like RNA polymerase II, TATA box binding protein (TBP)-associated factor, 50 kDa [Source:HGNC Symbol;Acc:11548] [ENSCAFT00000027954]
29	↓5.1920776	MYH2	Canis lupus familiaris myosin, heavy chain 2, skeletal muscle, adult (MYH2), mRNA [NM_001076795]
30	↓5.9604554	MYH1	Canis lupus familiaris myosin, heavy chain 1, skeletal muscle, adult (MYH1), mRNA [NM_001113717]
31	↓7.348387	POU1F1	Canis lupus familiaris POU class 1 homeobox 1 (POU1F1), mRNA [NM_001006949]

Fig. 2 Classification of up-regulated genes in canine mammary cancers of the 3rd grade of malignancy (a.) and in canine mammary cancers of the 1st grade of malignancy (b.) according to their involvement in biological processes (based on the PANTHER Database, www.pantherdb.org)



Calculator (free on-line access) and Primer-Blast (NCBI database). Primers' sequences are listed in Table 1. Rps19 gene was used as a non-regulated, reference gene for normalization of target gene expression (Brinkhof et al. 2006; Etschmann et al. 2006). Quantitative RT-PCR was performed using fluorogenic Lightcycler Fast Strand DNA Sybr Green (Roche) and the Light Cycler (Roche). The results were analyzed using comparative Ct method (Schmittgen and Livak 2008). Relative transcript abundance of the gene equals ΔCt values ($\Delta\text{Ct} = \text{Ct}^{\text{reference}} - \text{Ct}^{\text{target}}$). Relative gene expression is expressed as $\Delta\Delta\text{Ct}$ value ($\Delta\Delta\text{Ct} = 2^{-\Delta\text{Ct}}$). The experiment was conducted in triplicates.

Then, to visualize the PCR product it was dedicated for electrophoresis in 2 % agarose gel (Sigma Aldrich), stained with ethidium bromide (Sigma Aldrich) and run for 60 min at 90 mV in 1× tris-borate-EDTA buffer. Then, the gel was visualized under UV light.

Results

Gene expression in canine mammary malignancy

The microarray-based transcriptional profile of the canine mammary cancers of the 3rd grade of malignancy was




Fig. 3 Results for agarose gel electrophoresis of examined gene's PCR products following real time Sybr green amplification (a.). The RT-qPCR expression of examined genes ($n=3$) (b.). Estimated relative gene expression for each gene was compared between canine

mammary carcinomas of the 3rd grade of malignancy and of the 1st grade of malignancy (ANOVA and Tukey test; Graph Pad Prism 3.0, USA). The p value <0.05 was regarded as significant and marked as *, $p < 0.001$ was regarded as highly significant and marked as **

compared to the canine mammary cancers of the 1st grade of malignancy used as a reference. For each comparison 2 separate dye-swap experiments were performed. This study showed 70 statistically significant ($p < 0.005$; Fold change = 1.5) regulated genes (Fig. 1). Further analysis showed 39 up-regulated genes (Table 2) and 31 down-regulated genes (Table 3) in canine mammary cancer of the 3rd grade of malignancy.

Function of identified genes

PANTHER analysis of identified up-regulated genes showed that they were mainly involved in biological processes such as: cellular process (NELL2, NELL1, CNGA1, PRKCQ, S100P, EMR3, PCSK2, IL15, IL8, MARCO, IL6, CAMP, GPM6A, BCL2A1), metabolic process (MMP3, LEF1, ADCY8, CELA1, PRKCQ, LYZL6, TFPI2, S100P, MMP1, PCSK2, MTMR10, CAMP, AMP3, EXTL3) and developmental process (NELL2, NELL1, PRKCQ, EMR3, PCSK2, IL8, GPM6A, BCL2A1) (Fig. 2a). The most significant pathway in which up-regulated genes ($n=12$) were involved was the inflammation mediated by chemokine and cytokine signaling pathway (HLA-DQB1, NELL1, LYZL6, S100P, TFPI2, TREM1, EMR3, IL6, IL8, IL15, MARCO, CAMP). Analysis of the down-regulated genes showed that they were involved mainly in metabolic process, cellular process, cell communication and developmental process (Fig. 2b). Pathway analysis showed that these genes were mainly involved in cytoskeletal regulation by Rho GTPase, GnRH receptor pathway, inflammation mediated by chemokine and cytokine, nicotinic acetylcholine receptor signaling pathway and Wnt signaling pathway.

Real-time qPCR gene expression

For the purpose of microarray data validation, we have randomly selected 4 genes: il15, ergic2, elspb1 and extl3. Real-time qPCR results showed similar trends in gene expression changes as were observed in microarray studies (Fig. 3). The expression of examined genes was higher in the most malignant canine mammary cancers than in the tumours of the 1st grade of malignancy.

Discussion

Canine mammary cancer constitutes a serious clinical problem. That is a reason why its molecular biology has been systematically examined during the last few years (Rao et al. 2009; Pawłowski et al. 2011, Klopfleish et al. 2010; Pawłowski et al. 2013).

The very interesting study was conducted by Klopfleish et al. (2010) who identified a gene expression profile in canine mammary tumours that was associated with early metastatic spread to the lymph nodes. Based on the gene expression pattern of these tumours the authors were able to discriminate carcinomas with divergent metastatic potential despite similar histological features. Moreover, a partial overlap was found between the canine mammary “metastatic” gene expression profile and similar metastasis-associated gene expression “signature” of breast cancer (Veer et al. 2002).

Our previous study of gene expression in canine mammary tumours of various grade of malignancy showed that histological diagnosis was distinct from molecular diagnosis (Pawłowski et al. 2013). We have also identified cellular pathways and biological processes in which the most

significant up-regulated genes were involved. In the tumours of the 3rd grade of malignancy we identified interesting up-regulated cluster of genes related to immunological system. Their higher expression found in the most malignant cancers might be related with increased recruitment of hematopoietic cells into the tumour mass. Although the tumour is composed of various cells depending on the tumour type, myeloid cells seem to form a major component (Bingle et al. 2002). Clinical studies have shown a correlation between the number of myeloid cells (mainly macrophages) and a poor prognosis in many human cancers (e.g. breast, prostate, ovarian, etc.) (Jadus et al. 1996). Our own studies conducted on canine mammary cancers have not shown any correlation between number of macrophages in tumour mass and a grade of tumour malignancy (Król et al. 2011). However, interestingly we observed expression of myeloid cell antigens in cancer cell lines and tissues (Król et al. 2011, 2012) which increased upon the co-culture of these both types of cells (Król et al. 2012). We have shown that expression of typical macrophage antigens (CD14, CSF-1R) in canine mammary cancer tissues correlated with the tumour grade of malignancy (Król et al. 2011). Similarly, Dr. Pollard (2008) described that a gene expression signature characteristic for macrophages was an independent predictor of poor outcome in follicular lymphoma. Thus, these genes were typed as new malignancy markers.

Based on these results, the aim of the presented study was two-fold: 1) to compare gene expression in canine mammary tumours of the 1st and the 3rd grade malignancy in order to find new possible prognostic markers and 2) to validate whether genes characteristic for immunological system can constitute new markers of malignancy.

Similarly to our previous study (Pawłowski et al. 2013) we showed significant over-manifestation of genes related with chemokine and cytokine mediated signalling pathway (HLA-DQB1, NELL1, LYZL6, S100P, TFPI2, TREM1, EMR3, IL6, IL8, IL15, MARCO, CAMP) (Fig. 2, Tables 2 and 3). A few of these genes seemed to be particularly interesting. For example, S100P calcium binding protein (which expression is regulated by androgens and IL6 – another up-regulated gene in the most malignant canine mammary tumours) is thought as a new prognostic factor (Parkkila et al. 2008). A correlation was found between its increased expression and poor survival, cancer proliferation and increased resistance to chemotherapy (Maciejczyk et al. 2013). Our results are in accordance with clinical data as the cancers of high grade of malignancy (which express higher levels of S100P) are associated with an increased risk of death within 2 years after mastectomy (Karayannopoulou et al. 2005).

In the most malignant canine mammary cancers an increased expression of two metalloproteinases (MMPs): 1 and 3 was observed (Table 2). MMPs comprise a structurally and functionally related family degrading extracellular matrix

and basement membrane barriers. That is why they are thought to play a key role in angiogenesis, inflammatory processes, cancer development and metastasis, as well as in proliferation and apoptosis (Sauter et al. 2008). Because of their role in the degradation of the extracellular matrix leading to tumor invasion and metastasis, they may also serve as prognostic markers (Pardo and Selman 2005, Brickerhoff and Matrisian 2002). In this context, MMPs have been focused on as targets for therapeutic strategies.

The metalloproteinases are also linked to specific aspects of an inflammatory or immune response, such as the generation of chemokine gradients or immune cell influx (Hojilla et al. 2008). In addition to the metalloproteinase-mediated generation of inflammation triggers, metalloproteinases are, in turn, utilized by immune cells to further propagate the inflammatory reaction. In breast cancer samples, MMPs are found in neutrophils, macrophages, and T lymphocytes as well as in cancer cells (Benaud et al. 1998).

Cancer development is a complex process. In addition to the cancer cell intrinsic factors, the cancer microenvironment composed of various cells influences the behavior of cancer cells. The results of our study indicate that in dogs the number of tumour-infiltrating myeloid cells or expression of myeloid-specific antigens by cancer cells is related to the cancer progression and may constitute a new marker of malignancy, however further studies in this field are required.

Acknowledgments This work was supported by grant no N N308 574940 from the Ministry of Sciences and Higher Education. The authors would like to thank prof. Dr. hab. Elżbieta Malicka and Dr. Izabella Dolka from Warsaw University of Life Sciences for histopathological diagnosis of examined canine mammary tumours.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Benaud C, Dickson RB, Thompson EW (1998) Roles of the matrix metalloproteinases in mammary gland development and cancer. *Breast Cancer Res Treat* 50:97–116
- Bingle L, Brown NJ, Lewis CE (2002) The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. *J Pathol* 196:254–265
- Brickerhoff CE, Matrisian LM (2002) Matrix metalloproteinases: a tail of a frog that became a prince. *Nat Rev Mol Cell Biol* 3:207–214
- Brinkhof B, Spee B, Rothuizen J, Penning LC (2006) Development and evaluation of canine reference genes for accurate quantification of gene expression. *Anal Biochem* 356:36–43
- Etschmann B, Wilcken B, Stoevesand K, von der Schulenburg A, Sterner-Kock A (2006) Selection of reference genes for quantitative real-time PCR analysis in canine mammary tumors using the GeNorm algorithm. *Vet Pathol* 43:934–942

- Hojilla CV, Wood GA, Khokha R (2008) Inflammation and breast cancer. Metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. *Breast Cancer Res* 10:205
- Jadus MR, Irwin MC, Irwin MR, Horansky RD, Sekhon S, Pepper KA, Kohn DB, Wepsic HT (1996) Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. *Blood* 87:5232–5241.
- Karayannopoulou M, Kaldrymidou E, Constantiniadis TC, Dessiris A (2005) Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. *J Comp Pathol* 133:246–252
- Klopfleisch R, Lenze D, Hummel M, Gruber AD (2010) Metastatic canine mammary carcinomas can be identified by a gene expression profile that partly overlaps with human breast cancer profiles. *BMC Cancer* 10:618
- Król M, Pawłowski KM, Majchrzak K, Dolka I, Abramowicz A, Szyszko K, Motyl T (2011) Density of tumor-associated macrophages (TAMs) and expression of their growth factor receptor MCSF-R and CD14 in canine mammary adenocarcinomas of various grade of malignancy and metastasis. *Pol J Vet Sci* 14:3–10
- Król M, Pawłowski KM, Majchrzak K, Gajewska M, Majewska A, Motyl T (2012) Global gene expression profiles of canine macrophages and canine mammary cancer cells grown as a co-culture in vitro. *BMC Vet Res* 8:16
- MacEwen EG (1990) Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. *Cancer Metastasis Rev* 9:125–136
- Maciejczyk A, Lacko A, Ekiert M, Jagoda E, Wysocka T, Matkowski R, Hałoń A, Gyorffy B, Lage H, Surowiak P (2013) Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. *Histol Histopathol*, ahead of publication
- Manali E, de Giuseppe A, Feliziani F, Forti K, Casciari C, Marchesi MC, Pacifico E, Pawłowski KM, Majchrzak K, Król M (2012) CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. *BMC Vet Res* 8:86
- Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, Rabkin S, Guo N, Muruganujan A, Doremiex O, Campbell MJ, Kitano H, Thomas PD (2005) The PANTHER database of protein families, subfamilies, functions and pathways. *Nucleic Acids Res* 33:D284–D288
- Misdorp W (2002) Tumors of the mammary gland. In: Meuten DJ (ed) *Tumors in domestic animals*. Iowa State Press, Ames, pp 575–606
- Misdorp W (1991) Progestagens and mammary tumours in dogs and cats. *Acta Endocrinol* 125(suppl 1):27–31
- Misdorp W, Else RW, Hellme'n E, Lipscomb TP (1999) Histological classification of mammary tumors of the dog and the cat. Armed Forces Institute of Pathology and the American Registry of Pathology and The World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology, Washington, D.C., USA 7:11–29
- Pardo A, Selman M (2005) MMP-1: the elder of the family. *Int J Biochem Cell Biol* 37:283–288
- Parkkila S, Pan P, Ward A, Gibadulinova A, Oveckova I, Pasterkova S, Pastorek J, Martinez AR, Helin HO, Isola J (2008) The calcium-binding protein S100P in normal and malignant human tissues. *BMC Clin Pathol* 8:2
- Pawłowski KM, Majewska A, Szyszko K, Dolka I, Motyl T, Król M (2011) Gene expression pattern in canine mammary osteosarcoma. *Pol J Vet Sci* 14:11–20
- Pawłowski KM, Popielarz D, Szyszko K, Gajewska M, Motyl T, Król M (2012) Growth Hormone Receptor (ghr) RNAi decreases proliferation and enhances apoptosis in CMT-U27 canine mammary carcinoma cell lines. *Vet Comp Oncol* 10:2–15
- Pawłowski KM, Maciejewski H, Dolka I, Mol JA, Motyl T, Król M (2013) Gene expression profiles of canine mammary carcinoma of various grade of malignancy. *BMC Vet Res*, in review
- Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. *J Leukoc Biol* 84:623–630
- Rao NS, van Wolferen ME, Gracanin A, Bhatti SF, Krol M, Holdtege FC, Mol JA (2009) Gene expression profiles of progesterin-induced canine mammary hyperplasia and spontaneous mammary tumors. *J Physiol Pharmacol Suppl* 1:73–84
- Russo IH, Russo J (1998) Role of hormones in mammary cancer initiation and progression. *J Mammary Gland Biol Neoplasia* 3:49–61
- Sauter W, Rosenberger A, Beckmann L, Kropp S, Mittelstrass K, Timofeeva M, Wolke G, Steinwachs A, Scheinter D, Meese E, Sybrecht G, Kronenberg F, Deinermann H, Chang-Claude J, Illig T, Wichmann HE, Bickeboller H, Risch A (2008) Matrix Metalloproteinase 1 (MMP1) is associated with early onset lung cancer. *Cancer Epidemiol Biomarkers Prev* 17:1127
- Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative Ct method. *Nature Prot* 3:1101–1108
- Veer van't LJ, Bernards R (2008) Enabling personalized medicine through analysis of gene-expression patterns. *Nature* 452:564–570
- Veer van't LJ, Dai H, Vijver can de MJ, He YD, Hart AA, Mao M, Peterse HL, Koy van der K, Marton MJ, Witteveen AT (2002) Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 415(6871):530–536